Reviva Pharmaceuticals

Historical price data

Reviva Pharmaceuticals is a clinical-stage biotech focused on addressing high-burden diseases with significant unmet medical needs, primarily in neuropsychiatry. Its core strategy is built around its internally discovered lead candidate, brilaroxazine, which demonstrated positive topline results in a pivotal Phase 3 schizophrenia trial (RECOVER) and is being developed for a broad spectrum of CNS indications. The company is navigating the late-stage regulatory pathway, having received FDA feedback requiring a second Phase 3 trial prior to an NDA submission, while concurrently advancing a second pipeline candidate, RP1208, for pulmonary and metabolic conditions. Reviva aims to establish brilaroxazine as a potential best-in-class, broad-spectrum neuropsychiatric therapy.

A chemical genomics-driven platform that integrates genomics and chemistry to identify novel drug targets and new chemical entities (NCEs) with the aim of predicting efficacy and safety profiles earlier in the discovery process.

Brilaroxazine competes in the crowded schizophrenia market against established atypical antipsychotics and novel agents like Karuna's KarXT. Its primary proposed differentiation is a favorable metabolic and safety profile. As a micro-cap company, Reviva also competes for investor capital and future partnership attention against larger, more diversified biotechs.